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"Be not afraid of going slowly; 
be afraid of standing still." 
-Japanese proverb 
Computer Assisted Physician Order Entrv 
A member of the medical staff observed that the new 
computerized system will need the same qualities that are 
essential to starting a new medical practice: availability, 
affability (read user-friendly) and ability. At a prior meeting, 
Medical Executive Committee membership was virtually 
unanimous in emphasizing the user-friendly aspect. If a new 
system requires multiple screens and considerable extra time, 
physicians will be understandably reluctant to adopt it. 
REPORTS OF MEDICAL ERRORS IN U.S. HOSPITALS ARE 
STRONGLY INFLUENCING WHERE AMERICANS CHOOSE 
TO GO FOR THEIR HEALTH CARE. According to a survey of 
2000 Americans by the Kaiser Family Foundation and the 
federal Agency for Healthcare Research and Quality (AHRQ), 
physician and hospital error rates were ranked by respondents 
at the top of their lists in deciding which hospitals or health 
plans deliver quality care, while 70 percent said that medical 
error rates tell them "a lot" about the quality of care a hospital 
or health plan can deliver, Yahoo News reported. The survey 
said that half of all American adults fear that a medical error 
will affect them or their families when receiving general health 
care services, and noted that consumers are not receiving 
more useful measures of health care quality, Yahoo News 
added. (Yahoo News, December 11, 2000) 
http://dailynews. yahoo.com/h/nm/2000 1211/hl/errors 1. html 
This system of using the computer to enter medical orders is 
new to most of the LVH medical staff, but is not new to an 
increasing number of hospitals in the country. We are teaming 
from them as we start trials using Fujitsu wireless handheld 
units that offer mobile access to the Phamis system. 
The system will reduce errors by reducing adverse drug 
interactions, allergies, wrong drug or dose due to illegibility of 
handwriting or signature. It will improve use of guidelines and 
clinical pathways, improve choice of cost-effective drugs, and 
improve clinical research utilization. The ultimate goal is 
improved quality of care. Insurers and the public will demand 
this as a quality issue in the near future. 
(Continued on Page 2) 
(Continued from Page 1) 
Members of the LVPHO 1/S Committee and Dr. Don Levick 
have been working hard on this critical project at several 
different levels. Don will discuss this further at the Medical 
Executive Committee meeting in February. 
CAT Fund and the Malpractice Crisis in Pennsylvania 
INCREASES IN MALPRACTICE INSURANCE PREMIUMS 
COULD LEAD TO SHORTAGES IN SURGEONS, 
NEUROSURGEONS, OBSTETRICIANS AND OTHER 
SPECIAL TIES IN THE PHILADELPHIA AREA. At Frankford 
Hospital's three facilities in Northeast Philadelphia and Bucks 
County, all12 active orthopedic surgeons decided to put down 
their scalpels after their malpractice rates nearly doubled to 
$106,000 each for 2001, reported the Philadelphia Inquirer. 
Philadelphia juries have in recent months awarded a string of 
record-setting, multi-million-dollar verdicts, while physicians in 
counties surrounding Philadelphia are apparently being sued in 
Philadelphia courts in increasing numbers because of the ease 
with which plaintiff attorneys can shift trial venues. Only New 
York pays out more than Pennsylvania in malpractice awards, 
while Philadelphia alone paid out more in 1998 malpractice 
cases than the entire state of California, according to data from 
the National Association of Insurance Commissioners. 
(Philadelphia Inquirer, December 31, 2000) 
http://www. phillynews.corn/content/ing uirer/2000/12/31/front 
paqe/MEDMAL31.ht 
MALPRACTICE AWARDS SURGE IN PA 
http://physiciansnews.com/cover/1 01.html 
Plaintiffs attorneys now seek the Philadelphia venue for their 
malpractice trials due to the track record of awards there. 
While the reason for this problem to be focused in 
Pennsylvania (especially Philadelphia) is not clear (at least to 
me), there is no question that we have a crisis brewing. We 
will be discussing the malpractice surge and the CAT Fund at 
the Medical Executive Committee meeting in February and, 
hopefully, will have some advice on this issue that affects us 
all. 
Conundrum: On one hand, experts from the American College 
of Surgeons and other sources advise us that solutions for 
medical errors require a non-punitive systems approach to 
identify the real underlying source of the error. On the other 
hand, the present legal system is clearly punitive, very 
expensive, and has not been successful in the past in 
eliminating medical errors (otherwise the number of 
malpractice cases would surely be declining by now). It is hard 
to escape the conclusion that our legal system has actually 
become an expensive impediment to improving the health care 
delivery system in this country. 
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Everybody can be great... because anybody can serve. You 
don't have to have a college degree to serve. You don't have 
to make your subject and verb agree to serve ... You only need 
a heart full of grace. A soul generated by love. 
- Martin Luther King, Jr. 
Respect 
We will continue to highlight the goals of the medical staff 
leadership on a recurring basis in Medical Staff Progress 
Notes. We endeavor to respect and value each member of 
the medical staff as a professional with a contribution to make. 
We understand the practice pressures, monetary pressures 
and time pressures that you live with daily. Your presence on 
the LVH medical staff is the culmination of years of hard work, 
credentialing, continuing professional education and constant 
scrutiny by government and managed care, as you focus on 
delivering quality medical and dental care to your patients and 
the community you serve. We all need to keep this "frame of 
reference" when interacting as members of the LVH team and 
maintain a mutual attitude of respect. This may not always be 
easy- from the Latin (notum easium). 
TEAMWORK = WE CAN DO MORE TOGETHER 
e~~o~ 
Edward M. Mullin, Jr., MD 
Medical Staff President 
· Pro tempore 
l!'.Janupry, in an effort to ~eep t~e Medical 
Staff informed in a timely manner of any· 
changjng developments. on the hospit(ll/medital 
scene, the Medical Stafft'eadership instit'uted . 
an informa.l e-.m(lil·messoge which will appear 
between the editions of Mediet~l Staff 
Progre~s Note.s. This new conl'munique will be 
caHed·Pf!o tempore (meaning''for the time 
being").· This e-ma,il upc{afe,will appe(lr aroun~ 
mid:-month, while Med1'col Stoff'Rrogress . 
Notesqr,e published at the beginnjng of each 
month. Pro tem{SOrewill also include.agenda 
topics for the upcoming Me~ical Executive 
Committee meeting. 'T'hls n~w communique is . 
anot~er: step toward an electronic 
communiCation.syste!'T', which is a goal o.f ·the 
Me~icai Staff Leadership. 
News from CAPOE Central 
The CAPOE project continues to make progress. Members of 
the 1/S Department and I have begun to make rounds with the 
Trauma team to learn their work process. This will help in the 
design and implementation of CAPOE. The Design Team has 
also begun to meet. This is a group of physicians, nurses and 
support staff who will provide input and feedback regarding the 
screen design and user interface of the CAPOE system. The 
members have been provided with a test version of the 
system, and will be dealing with specific design issues over the 
next several weeks. I am encouraged by everyone's interest 
and enthusiasm, especially given that the meetings begin at 
6:30a.m. The members of the Design Team will also serve as 
resources for the Medical Staff. If you would like a demo of the 
system, please contact me or any member of the Design Team 
listed below. 
Members ofthe Design Team 
• Don Belmont, MD 
• David Caccese, MD 
• Dave Carney, MD 
• Michael Ehrig, MD 
• Larry Glazerman, MD 
• Rick MacKenzie, MD 
• Rovinder Sandhu, MD 
• Brian Stella, MD 
• Jeff Faidley, MD, Internal Medicine Resident 
• William Bromberg, MD, Chief Surgical Resident 
• Betsy Davies, PA 
• Daniele Shollenberger, CRNP 
The PHO 1/S Committee met on January 15, 2001. The main 
thrust of the group will be to investigate the various office-
based prescription writing systems (i.e., iScribe, AIIScripts, 
PHAMIS/IDX PrescriptionPad). The group will attempt to 
identify a computerized prescription writing system that is most 
compatible with the majority of office practice management 
systems. We then hope to negotiate the best deal for our 
membership. We strongly encourage input from the medical 
staff. Please let me know your experiences with any of these 
systems, or if you would like to participate in this process. 
Don Levick, MD, MBA 
Chair, LVPHO 1/S Committee 
Phone: (484) 884-4593 
Urologic Cancer Second Opinion 
Service 
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In an effort to provide a needed service for patients in the 
Lehigh Valley area and attract out-of-area patients, the 
Urologic Cancer Second Opinion Service was developed. This 
service, which opened at LVH-Muhlenberg in July, 2000, is the 
first of its kind in the region and features four LVHHN 
specialists --Victor M. Aviles, MD, medical oncologist; Steven 
J. Perch, MD, radiation oncologist; Melvin L. Steinbock, MD, 
urologist, and Joseph G. Trapasso, MD, the region's only 
fellowship-trained urologic oncologist. 
"People diagnosed with prostate, bladder, kidney or testicular 
cancer often have questions about side effects, risks and the 
best treatment," said Gregory R. Harper, MD, physician-in-
chief of cancer services. "Our team evaluates patients in one 
visit and gives them a personal and written explanation of the 
recommendation, helping relieve some of their fear, confusion, 
and anxiety. 
According to Dr. Harper, the service works closely with 
referring physicians by offering their patients convenient local 
access to second opinions. For the first time, area residents 
can get a second opinion for urologic cancer without having to 
travel to Philadelphia or New York. Patients are expected from 
as far north as Binghamton, NY, as far east as north-central 
New Jersey, as far west as Lancaster, and as far south as 
Montgomery, Bucks and Chester counties. 
The new service is a component of LVHHN Cancer Services 
that offers the latest diagnostic and treatment methods, 
including the area's most experienced laparoscopic surgery 
and the region's most experienced radioactive seed implants 
program. Patients are also offered information about a variety 
of urologic clinical trials and national research studies for 
treatment and prevention that are available through Cancer 
Services. 
For more information regarding the Urologic Cancer Second 
Opinion Service, please call (610) 402-CARE (2273). 
c .• · • •• • • . ·'' 
.For ~our CoJendt!r 
Tb~ fourth triennial Ptwsicicm Recognhion 
Dinne~ will be held on Saturd~y, March 31, 
at the'"Holidcty tnn.Conference·Center in· 
fogelsville .. In~Itations· will be mailed in · ·. 
February-.· Please. mark :yo.ur calendC:u~J . 
''., ' ' 
E-mail Surrogates 
With e-mail being used more and more frequently to 
communicate information to the Medical Staff, all members of 
the Medical Staff are encouraged to read their e-mail regularly 
or to designate a staff member to be your appointed 
"surrogate" who can read and print out your e-mail messages 
for you on a daily basis. 
To make life easier for you, following are instructions for 
setting up a surrogate: 
Step 1 • Instructions for the User 
To define a surrogate, you must specify the user(s) who you 
wish to name as surrogate and select the features the 
surrogate will be authorized to access. 
1. From the main menu, choose Tools, Configure, and TAO 
Profile Option 
2. Click the Surrogates tab 
3. In the Current Surrogates box, either type in the MaiiiD of 
the user you want to name as surrogate or click the Select 
button to select a MaiiiD from the MaiiiD Directory. To 
delete a MaiiiD, select the MaiiiD and press the Delete 
Key. When you remove a surrogate from the list, that user 
no longer has permission to act as your surrogate. To 
designate all users on your system as your surrogates, 
without references to class or department, enter 
*EVERYONE in the Edit box. To specify all members of 
your department as your surrogates, enter 
*DEPARTMENT in the Edit box. 
4. In the Surrogate Abilities box, check the surrogate 
functions you want to grant to your surrogate(s). You may 
update a surrogate at any time to reassign powers. Select 
the desired MaiiiD in the Current Surrogates box and then 
click the checkbox next to the function you want your 
surrogate to perform. Repeat this step for each MaiiiD to 
receive surrogate powers. 
Step 2 • Instructions for the Surrogate 
Having access to Surrogate mode does not mean that you can 
act as someone's surrogate. Someone must have named you 
as surrogate and granted you powers in order for you to sign 
on to their account. 
1. To enter Surrogate mode, choose File, Surrogate Mode. 
The Surrogate For dialog displays. 
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2. Use the Search box or scroll bar to locate the MaiiiD of 
the person for whom you wish to act as surrogate. 
Double-click the desired Mail I D. It appears in the 
Surrogate For box. Click OK to confirm your selection. 
The TAO user whose MaiiiD you specify must have 
designated you as their surrogate. If not, a message 
displays notifying you that you have not been defined as a 
surrogate. Once TAO recognizes you as a surrogate, the 
main TAO window displays. The Folder list and icon bar 
reflect the features that you can access. 
3. When you have completed your surrogate a.ctivities and 
are ready to exit Surrogate mode, choose F1le, End 
Surrogate Mode. 
If you or the person who you wish to become your 
surrogate is not currently on the hospital's e-mail system, 
please contact Pat Skrovanek in Physician Relations at 
(610) 402·9190. 
Infection Control Notices 
PreOp Showering 
This is a reminder that chlorhexidine (Hibiclens) is the 
preferred antiseptic agent for pre-operative showering. 
Surgeons and their staff are encouraged to ~ecom'!len~ the 
use of Hibiclens as the preferred pre-operative ant1sept1c agent 
when instructing patients to shower/bathe prior to surgery. 
Hibiclens is available at all three Health Spectrum Pharmacies 
(Cedar Crest & 1-78, 17th & Chew and LVH-M) at a nominal 
cost to the patient. 
Influenza 
Influenza A and B are both circulating in the community. There 
is still time to vaccinate patients and their caregivers before the 
impact of the flu becomes severe. Delays in the manufacturing 
of the vaccine have subsided and full supplies are available. 
Aggressive measures to catch up on vaccinating patients at 
risk are needed to curb the effects of this potentially 
devastating virus. 
If you have any questions, please contact the Infection Control 
Department at (610) 402-0680. 
News from the Health Information 
Management Department 
Document Imaging Update 
Cedar Crest & 1-78, 17fh & Chew and Westgate (Behavioral 
Health Science Center) - The Health Information Management 
(HIM) Department is currently in the implementation phase for 
the document imaging (Pathways Image Manager) upgrade. 
System upgrade will provide enhanced functionality and better 
access to patient records. Because of an entirely new look 
and feel to the system screens, plus increased functionality, all 
physicians must receive additional training. The good news, 
however, is that the training will require about the same 
amount of time as the original training ... approximately 15-20 
minutes. Targeted implementation date for Cedar Crest & 
1-78, 17th & Chew, and Westgate is scheduled for April, 2001. 
LVH-M- Following completion of the LVH upgrade, 
implementation will begin at the LVH-M campus beginning in 
May, 2001. Targeted implementation is as follows: 
May, 2001 - Start scanning medical records into imaging 
system 
June, 2001 - Physician Training 
-Transition from paper to computerized 
access/record completion 
Please stay tuned for updates regarding implementation 
progress. 
Death Certificate Completion 
Effective February 1, the HIM Department will no longer have 
the assistance of a Decedent Affairs Consultant to assist with 
death certificate completion. The current process will remain 
the same with physicians being asked to complete one death 
certificate (including the cause of death) and signature and one 
signed to have the cause of death typed and legible. You are 
encouraged to complete the death certificate at the time the 
patient is pronounced and cause of death is determined. 
Death certificates not completed by the time the patient's chart 
has been removed from the office will be handled through the 
HIM Department at Cedar Crest & 1-78. Since this process is 
being handled in-house, death certificates will no longer be 
delivered to physician offices for signature/completion. The 
HIM staff will call to remind you of incomplete death 
certificates. 
Since the death certificate is not part of the patient's medical 
record, you are requested to include the (1) circumstances of 
patient's death, (2) cause of death, and (3) whether an autopsy 
was performed in the final progress note in the medical record. 
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Advance Directive, Living Will, Durable Power of Attorney 
The Patient Self-Determination Act mandates that all hospitals 
and other specified Medicare or Medicaid-funded health care 
facilities provide a mechanism for advising patients of their 
legal rights and options for refusing or accepting treatment if 
they are, or become, incapacitated. This can be done in the 
form of advance directives, living wills, durable power of 
attorney, do not resuscitate orders, right to die, etc. 
Although the Patient Care Services staff discuss Advance 
Directives with patients when they are admitted for services, 
one of the recommendations made by the Joint Commission 
during the December, 2000 survey was that physicians initiate 
this process when patients are seen in their office prior to 
receiving services at the hospital. By beginning this process 
when they are seen in the physician's office, patients have an 
opportunity to ask questions of the physician and prepare to 
have the documentation available at the time services are 
provided in the hospital. 
Suspension Process 
Since the medical record completion process is electronic at 
the Cedar Crest & 1-78, 17th & Chew, and Westgate 
(Behavioral Health Science Center) sites, physicians are again 
reminded to call the HIM Department at (610) 402-8240 once 
records are completed after suspension of privileges has been 
initiated. This will enable the HIM Department to notify the 
appropriate departments to resume admission privileges. 
Currently, there is no automated way for the system to notify 
HIM when the charts have been completed for physicians who 
have had privileges suspended. 
If you have any questions regarding these issues, please 
contact Zelda Greene, Director, Health Information 
Management, at (610) 402-8330. 
. ·coding Tip of the Month 
~~thma with Acute Exac~rbatipn - A chronic, 
stable ~onditibn is not necessarily an indication 
for admission to· the:hospital·unless the· 
p~tient just received this diagnosis for the 
first time or the disease .process has 
deter(orated significantly. In the case of 
as{~ma,please pe ·sure to d,.ocument if the 
patient, has acute.exacerbation,of asthma or 
chronic obstructive aSthma with acute 
·~ . ~ . ;. ' 
exacerbation. ,, 
Radiology News 
Imaging to Screen for Renal Artery Stenosis 
There are several imaging modalities available as screening 
tools to be used prior to more invasive angiography 
procedures in the evaluation of renal artery stenosis. 
Magnetic resonance arteriography (MRA) with Gadoliniun 
enhanced sequences provides arteriogram-like images of the 
renal arteries. Sensitivities and specificities of greater than 
90% are frequently reported in the literature. Advantages of 
MRA include the ability to obtain arteriogram-like images 
without the risk of nephrotoxic contrast material and the ability 
to evaluate the abdominal aorta prior to percutaneous or 
surgical intervention including the origin of the celiac artery (a 
potential source of inflow for surgical reconstruction). MRA 
can also provide functional information (i.e. delayed 
nephrogram) which may help determine the significance of a 
stenosis. Limitations of MRA include its frequent restriction to 
detection of stenoses of the main renal arteries as the 
divisional, segmental and small accessory arteries may be 
difficult to image reliably, visualize or grade accurately. Patient 
motion, metal/calcium artifacts and flow artifacts may degrade 
the images. Contraindications to MRA include the presence of 
a pacemaker or intraoccular metallic foreign body. 
Another technique that provides arteriogram-like images of the 
renal arteries is computed tomography arteriography (CTA). 
Imaging is performed by continuous acquisition of a volume of 
data as the patient is moved through the scanner during rapid 
intravenous injection of a large volume of iodinated contrast 
material, approximately 150 mi. Several studies have reported 
sensitivities and specificities of >I= 90% for detection of main 
renal artery stenosis. As with MRA, the entire abdominal aorta 
can be imaged allowing evaluation of concomitant aortic and 
visceral vessel disease. Unlike MRA, in which the signal from 
the background tissues is suppressed or absent, CTA retains 
anatomic information about all of the abdominal contents and 
the degree of vascular calcification is accurately depicted. The 
chief disadvantage of CTA is its absolute requirement for 
iodinated contrast material. The technique is therefore not 
suitable for patients with renal insufficiency or contrast material 
allergies. Other limitations include inconsistent visualization of 
small or accessory arteries and distal branches of the main 
renal artery. Heavily calcified plaque may obscure the vessel 
lumen, making stenoses difficult to grade. Patient motion or 
respiration during the examination creates artifacts that 
degrade image quality. 
Conventional ultrasound (US} may suggest renal artery 
stenosis when a small kidney is identified, but Doppler US is 
required for evaluation of renal artery flow. The diagnosis of 
renal artery stenosis is based upon the Doppler estimation of 
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blood flow rather than imaging of the actual lesion. The site of 
the lesion can be localized by a sudden increase in the peak 
systolic velocity within the vessel. However, determination of 
the peak systolic velocity alone is a poor indicator of significant 
renal artery stenosis and, as a result, other criteria have been 
proposed for the diagnosis of a hemodynamically significant 
lesion such as a ratio of the peak systolic velocity in the renal 
artery to that in the aorta of >I= 3.5, or delay in the measured 
systolic acceleration in segmental renal arteries. Doppler US 
has reported sensitivity of 95% and specificity of 90% for 
detection of renal artery stenosis >/= 60%. However, 
complete Doppler US interrogation may not be possible in as 
many as 15% of patients. Large body habitus, tortuous arterial 
anatomy, severe renal artery stenosis or occlusion, and 
multiple renal arteries seriously limit the usefulness of the 
study. Also, these studies are extremely technologist operator 
dependent and may be very time-consuming requiring up to 
two hours in a difficult patient and may end in an inadequate 
study requiring MRA for evaluation. 
Enalapril-stimulated nuclear studies image renal function and, 
indirectly renal artery flow. Renal artery stenosis is implied by 
decreased and delayed renal uptake of the 
radiopharmaceutical after the administration of Enalapril since 
Enalapril reduces the glomerular filtration pressure distal to the 
stenosis. In properly selected patients, the sensitivity of this 
test is approximately 90% and the specificity is approximately 
95%. Although false-positive studies are unusual, false-
negative results can occur in patients with bilateral disease, 
stenosis of one of multiple renal arteries, dehydration and 
azotemia. 
At LVH, the current recommendation is to utilize MRA as the 
screening procedure of choice in the detection of renal artery 
stenosis, although CTA or a nuclear study is a viable 
alternative, especially in patients who cannot remain still for 
the time required for an MRA study. 
If you have any questions, please contact Darryn Shaff, MD, 
Division of Diagnostic Radiology, at (610) 402-8088. 
The members of the Division of Hema:tology-Medical. 
Onco1ogy·have agreed to incorpor!lte, all patients from 
the 11~mdtology oncology clinic;into their private o,ffic:e 
practiees b¢ginning in February. 
The prifleipal sour.ces of referrals are medical and 
surgical clinic, inpatient tnedical and surgical.service' 
patients, and occasionally, other ':"edical staff or the 
stote hospifol. . · · · 
A l~tter to the Medico! Stoff communi~oting this chonge 
. on .. d 'the, new referral process is ahac~.ed on Page 15. 
' ' 
New Weight Management Program 
The Helwig Diabetes Center Weight Management Program is 
open and taking referrals. The program is designed to assist 
the patient who needs to lose a minimum of 60 pounds (BMI 
over 30) and has at least one co-morbidity. Individual goals 
will be determined for each patient and the program will be 
guided by the NIH algorithm for obesity. Keith R. Doram, MD, 
Chief, Division of Generallntemal Medicine, and Larry N. 
Merkle, MD, Chief, Division of Endocrinology-Metabolism, 
provide physician leadership for the program and have been 
instrumental in its development. Maintaining open 
communication with the referring physician is an important part 
of using the NIH weight management algorithm. The staff of 
the Helwig Diabetes Center works with the referring physician 
during the program and as evaluations for education 
medication and surgical options become relevant. ' 
The program includes two segments. The initial nutrition 
counseling includes an individual assessment, diet evaluation 
and meal planning with the patient. The second segment of 
the program is six months in length and includes four weeks of 
nutrition education, four weeks of supervised exercise 
(Exercise for Life Programs), and four months of supervised 
follow-up. All patients must be willing and able to participate in 
eac~ activity. The group exercise classes are instructed by 
certified fitness specialists and are sensitive to the needs of 
the obese individual. While the classes stress flexibility, 
strength training and conditioning, individuals participate 
according to tolerance at least three times a week. Nutrition 
education stresses behavioral change and healthy food 
selection including guidelines for shopping and restaurant 
meals. Supervised follow-up encourages the patient to 
maintain their program and allow the health educators to 
continue education and support. 
This program offers a unique, comprehensive approach to the 
treatment of the obese patient. For more information, please 
contact the Helwig Diabetes Center at (610) 402-5000. 
CHF Patients Sought for Clinical Trial 
Patients with Class Ill or IV congestive heart failure may qualify 
for the COMPANION clinical trial, which is testing the 
effectiveness of bi-ventricular cardiac synchronization in 
improving patients' survival rate, quality of life and ability to 
exercise, and decrease their length and frequency of 
hos~italiz.ation. The study is sponsored by the Guidant Corp. 
and 1s bemg conducted at LVH by Luis Constantin, MD, James 
Sandberg, MD, and Steven Zelenkofske, DO, members of the 
Division of Cardiology. 
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COMPANION is a randomized study in which participants will 
be placed in one of the following groups: 
•!• They will receive the CONTAK TR bi-ventricular 
pacemaker and optimal pharmacologic therapy; or 
•:• They will receive the combination CONTAK CD 
pacemaker/defibrillator and optimal pharmacologic 
therapy; or 
•!• They will receive only optimal pharmacologic therapy. 
Please consider referring a patient for possible enrollment in 
this trial, based on the following inclusion and exclusion 
criteria: 
Inclusion Criteria 
1. Moderate or severe symptomatic heart failure for at 
least 6 months at the time of enrollment 
2. Left or right bundle branch block with QRS > 120 ms 
3. Left ventricular ejection fraction< 35% -
4. Older than 18 years -
Exclusion Criteria 
1. Meet the general indications for an implantable 
cardioverter defibrillator and/or pacemaker 
2. Myocardial infarction within 60 days of randomization 
3. Life expectancy < 6 months due to any other medical 
condition 
To refer a patient to the COMPANION study, or to learn more 
about it, please call Patti Frey or Cherie Tyler, study 
coordinators for The Heart Care Group, at (610) 778-3667. 
More Clinical Trials 
Ne~roscienc~s .and ~ain Research is currently recruiting 
pat1ents for chmcal tnals in the following areas: 
•!• Adjuvant Cancer Pain - add-on therapy for patients who 
are currently on opioids. 
•:• Diabetic Neuropathy - patients who are experiencing 
polyneuropathy secondary to diabetes. 
•!• Constipation secondary to Opioid use - severe 
constipation, less than three bowel movements per week. 
May be using laxatives and other stool softeners. 
There are several inclusion and exclusion criteria for each 
study .. For mo.re information on any of the studies or if you 
would hke to d1scuss a potential candidate, please contact 
Maryjane Cerrone, RN, Clinical Research Specialist at (610) 
402-9008. , 
Cancer Survivorship Study 
Some of your patients who are cancer survivors may ask you 
about a study in which they have been asked or will be asked 
to participate. The study, funded by the National Cancer 
Institute, and administered by the Center for Health Policy 
Research at Penn State University, is a collaboration of Lehigh 
Valley Hospital, Hershey Medical Center, Geisinger, and Johns 
Hopkins Oncology Center. 
Patients identified by the tumor registries at the participating 
institutions who meet eligibility requirements are being asked if 
they would be willing to participate in a survey study about 
people who have had cancer. The study is designed to 
provide information about how their experience with cancer 
has affected them, especially employment and economic 
aspects of their life. The study has been reviewed and 
approved by the IRBs at each institution, and the Penn State 
University. 
One of the stipulations of each IRB was that contacts with 
patients would be made by people from their "home" institution. 
Members of the cancer program at LVH are currently 
undertaking follow-up inquiries, and some of your patients may 
ask you about the study. 
Responses are, of course, completely confidential, and will not 
be traceable to an individual respondent. The survivors have 
multiple opportunities to decline to participate, either by 
notifying by return postcard, declining when contacted by 
phone, or declining to continue during the questionnaire if they 
previously agreed to participate. 
If you have any questions regarding this study, please contact 
Gregory R. Harper, MD, PhD, Physician in Chief, Cancer 
Services, at (610} 402-0512. 
. WOtJND · ~RE SERVICES. 
are still 'ovailoble to you and yot:Jr patients at the 
Wound Healing Program at LVH ... M 'i. 
(formerly the Wound Care Center). 
Hours of Oper~tion: 
Mondoy through • Friday 
. 8:a.m. to 4:30 p.m. 
To.mC!ke an appointmen.t for your pc;~tients, 
plecise coif the Wound Healing Program · 
at (484) 884-2989. 
fo~ additiortaHnfo,.matfbn, plea~e call 
Ginger A.Holko, RN, BSI'\l; Director, . 
at (484) 884 .. 2.989. 
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Congratulations! 
John D. Karabasz, DMD, Chief, Division of Prosthodontics, 
was awarded the Leonard Pool Prize for Outstanding 
Contribution to Health Care in the Lehigh Valley for his efforts 
in supporting optimal fluoridation of the Allentown water 
supply. Dr. Karabasz has been the driving force behind the 
effort to organize community support to improve the dental 
health of the citizens of Allentown. He has dedicated many 
hours to raising community awareness to the benefits of 
fluoride through his work with the Allentown-based Citizens for 
Children's Dental Health activities. 
William J. Smolinski, DO, Division of Cardiology, was 
recently elected to Fellowship in the American College of 
Physicians - American Society of Internal Medicine. 
Upcoming Seminars, Conferences and 
Meetings 
Medical Grand Rounds 
Medical Grand Rounds are held every Tuesday beginning at 
noon in the Auditorium of Lehigh Valley Hospital, Cedar Crest 
& 1-78, and via videoconference in the First Floor Conference 
Room at Lehigh Valley Hospital-Muhlenberg. 
Topics to be discussed in February will include: 
•!• February 6- New Techniques in Electrophysiology 
•:• February 13 - Breast and Prostate Cancer Chemo 
Prevention Trials 
•!• February 20- Under and Over Eaters-- Young and Old: 
A Panel Discussion 
•!• February 27 - Gastroesophageal Reflux and Esophageal 
Cancer 
For more information, contact Diane Biernacki in the 
Deparmtent of Medicine at (610} 402-5200. 
Department of Pediatrics Conference 
"Update on Pediatric HIV Infection: Trends, Tests and 
Therapies" will be presented on Tuesday, February 6, 
beginning at 8 a.m., in the hospital's Auditorium at Cedar Crest 
& 1-78. 
For more information, please contact Kelli Ripperger in the 
Department of Pediatrics at (610) 402-2540. 
Papers, Publications and Presentations 
"My Bride," an oil painting by John A. Altobelli, MD, Division 
of Plastic Surgery, was featured on the cover of the 
November/December 2000 issue of the Aesthetic Surgery 
Journal. 
George A. Arangio, MD, Division of Orthopedic Surgery, 
Section of Ortho Trauma, completed the visiting clinician 
program in Foot and Ankle Surgery at the Rizzoli Orthopedic 
Institute in Bologna, Italy. While he was there, Dr. Arangio 
presented clinical applications of a mathematical model of the 
foot and ankle to the Department of Orthopedics and · 
Biomechanics. 
Victor M. Aviles, MD, Associate Chief, Division of 
Hematology-Medical Oncology, co-authored two articles. The 
first article, "Tall Cell Papillary Carcinoma of the Thyroid: 
Metastatic to the Pancreas," was published in the February, 
2000 issue of Thyroid. The second article, "Pilot Study of 
Organ Preservation Multimodality Therapy for Locally 
Advanced Resectable Oropharyngeal Carcinoma," was 
published in the October, 2000 issue of the American Journal 
of Clinical Oncology. In addition, Dr. Aviles co-authored 
"Care of the Cancer Patient with Neutropenia and 
Thrombocytopenia," a chapter which appears in The Intensive 
Care Unit Manual, which was published last year by W. B. 
Saunders. 
Mark A. Gittleman, MD, Division of General Surgery, recently 
had an editorial published in the October, 2000 issue of The 
American Journal of Surgery. The editorial was titled "The 
Surgeon and Breast Ultrasonography Procedures." 
lndru T. Khubchandani, MD, Division of Colon and Rectal 
Surgery, was a visiting professor at Jaslok Hospital, Bombay, 
India, from January 6-14. He demonstrated endoscopic 
procedures and helped to organize the Association of Colon 
and Rectal Surgeons of India with the Executive Committee of 
the Group. 
Robert X. Murphy, Jr., MD, Division of Plastic Surgery/Hand 
Surgery, Section of Bum; K. Lesley Birmingham, MD, former 
Plastic Surgery resident; Walter J. Okunski, MD, Division of 
Plastic Surgery/Hand Surgery, Section of Bum; and Thomas 
E. Wasser, PhD, Department of Health Studies, co-authored 
an article, "Influence of Restraining Devices on Patterns of 
Pediatric Facial Trauma in Motor Vehicle Collisions," which 
was published in the January, 2001 issue of the Journal of 
Plastic and Reconstructive Surgery. 
Four members of the Division of Colon and Rectal Surgery --
Robert D. Riether, MD, John J. Stasik, MD, Chief, Lester 
Rosen, MD, and lndru T. Khubchandani, MD --co-authored 
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a paper with former Colon and Rectal Surgery resident, 
Khawaja Azimuddin, MD. The paper, "Transanal Endoscopic 
Microsurgery for Excision of Rectal Lesions: Technique and 
Initial Results," was published in the December, 2000 issue of 
Surgical Laparoscopy, Endoscopy & Percutaneous 
Techniques. 
Randolph Wojcik, MD, General Surgery resident, presented 
his paper, "Pre-injury Warfarini Does Not Impact Outcome in 
Trauma Patients," at the Eastern Association for the Surgery of 
Trauma Annual Meeting in Orlando, Fla., on January 11. Co-
authors of the paper are Mark D. Cipolle, MD, PhD, Chief, 
Section of Trauma Research, Elizabeth Seislove, RN, and 
Thomas E. Wasser, PhD, Department of Health Studies. 
Who's New 
The Who's New section of Medical Staff Progress Notes 
contains an update of new appointments, address changes, 
resignations, etc. Please remember to update your directory 
and rolodexes with this information. In addition, the Medical 
Staff Directory is now available on the e-mail Bulletin Board --
Directories. Updates will be made to the Medical Staff 
Directory in e-mail at the beginning of each month. 
Medical Staff 
New Appointments 
Richard E. Brannan, DO 
Primary Care Associates in the LV, PC 
1150 S. Cedar Crest Blvd., Suite 101 
Allentown, PA 18103-7900 
(610) 776-1603 + Fax: (610) 776-6344 
Department of Medicine 
Division of General Internal Medicine 
Site of Privileges - L VH & L VH-M 
Provisional Active 
Rene A. Chapados, MD 
CHOP-Pediatric Critical Care Medicine 
Children's Hospital of Philadelphia 
324 S. 34th Street 
Dept., Anesthesiology & Critical Care Medicine 
Philadelphia, PA 19104-4399 
(215) 590-5505 + Fax: (215) 590-4327 
Department of Pediatrics 
Division of Hospital Based Pediatrics 
Section of Critical Care Medicine 
Site of Privileges - LVH & L VH-M 
Provisional Limited Duty 
(Continued on Page 10) 
Robert J. Corba, DO 
Allentown Anesthesia Associates Inc 
The Center for Pain Management 
1240 S. Cedar Crest Blvd., Suite 307 
Allentown, PA 18103-6218 
(610) 402-1756 • Fax: (610) 402-1747 
Department of Anesthesiology 
Division of Pain Management 
Site of Privileges - LVH & L VH-M 
Provisional Active 
Daniela H. Davis, MD 
CHOP-Pediatric Critical Care Medicine 
Children's Hospital of Philadelphia 
324 S. 34th Street 
Dept., Anesthesiology & Critical Care Medicine 
Philadelphia, PA 19104-4399 
(215) 590-5505 • Fax: (215) 590-4327 
Department of Pediatrics 
Division of Hospital Based Pediatrics 
Section of Critical Care Medicine 
Site of Privileges - LVH & L VH-M 
Provisional Limited Duty 
Marguerite V. DeWitt, MD 
Forensic Pathology Associates Inc 
Lehigh Valley Hospital 
Cedar Crest & 1-78, P.O. Box 689 
Allentown, PA 18105-1556 
(610) 402-8144 • Fax: (610) 402-5637 
Department of Pathology 
Division of Anatomic Pathology 
Section of Forensic Pathology 
Site of Privileges - L VH & L VH-M 
Provisional Active 
Cromwell C. Estrada, DO 
19th Street Family Health Care, PC 
19th Street Health Center 
1901 Hamilton Street, Suite 2 
Allentown, PA 18104-6413 
(610) 437-7181 • Fax: (610) 435-0597 
Department of Family Practice 
Site of Privileges - LVH & L VH-M 
Provisional Active 
HongJin, MD 
Children's Heart Center of Northeastern PA 
Allentown Medical Center 
401 N. 17th Street, Suite 309 
Allentown, PA 18104-5050 
(610) 437-6687 • Fax: (610) 437-5232 
Department of Pediatrics 
Division of Pediatric Subspecialties 
Section of Cardiology 
Site of Privileges - LVH & LVH-M 
Provisional Active 
Number2 
Eva R. Michael, MD 
(Solo Practice) 
1566 Eighth Avenue 
Bethlehem, PA 18018-1829 
(610) 691-8502 
Department of Family Practice 
Site of Privileges - LVH & L VH-M 
Provisional Active 
Joel D. Portnoy, MD 
CHOP-Pediatric Critical Care Medicine 
Children's Hospital of Philadelphia 
324 S. 34th Street 
Dept., Anesthesiology & Critical Care Medicine 
Philadelphia, PA 19104-4399 
(215) 590-5505 • Fax: (215) 590-4327 
Department of Pediatrics 
Division of Hospital Based Pediatrics 
Section of Critical Care Medicine 
Site of Privileges - LVH & L VH-M 
Provisional Limited Duty 
Steven E. Schultz, MD 
CHOP-Pediatric Critical Care Medicine 
Children's Hospital of Philadelphia 
324 S. 34th Street 
Dept., Anesthesiology & Critical Care Medicine 
Philadelphia, PA 19104-4399 
(215) 590-5505 • Fax: (215) 590-4327 
Department of Pediatrics 
Division of Hospital Based Pediatrics 
Section of Critical Care Medicine 
Site of Privileges - L VH & L VH-M 
Provisional Limited Duty 
Kimberly R. Sheets, MD 
Riverside Medical Associates 
Riverside Professional Center 
5649 Wynnewood Drive, Suite 203 
Laurys Station, PA 18059-1124 
(610) 261-1123 • Fax: (610) 262-1739 
Department of Family Practice 
Site of Privileges - LVH & L VH-M 
Provisional Affiliate 
Eric P. Wilson, MD 
Peripheral Vascular Surgeons, PC 
1259 S. Cedar Crest Blvd., Suite 301 
Allentown, PA 18103-6260 
(610) 439-0372 • Fax: (610) 439-8807 
Department of Surgery 
Division of Vascular Surgery 
Site of Privileges - LVH & L VH-M 
Provisional Active 
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Athena F. Zuppa, MD 
CHOP-Pediatric Critical Care Medicine 
Children's Hospital of Philadelphia 
324 S. 34111 Street 
Dept., Anesthesiology & Critical Care Medicine 
Philadelphia, PA 19104-4399 
(215) 590-5505 • Fax: (215) 590-4327 
Department of Pediatrics 
Division of Hospital Based Pediatrics 
Section of Critical Care Medicine 
Site of Privileges - LVH & LVH-M 
Provisional Limited Duty 
Appointments to Medical Staff Leadership Positions 
George A. Aranglo, MD 
Department of Surgery 
Division of Orthopedic Surgery 
Section of Ortho Trauma 
Position: Chief, Section of Foot and Ankle Surgery 
Ravindra Bollu, MD 
Department of Medicine 
Division of Nephrology 
Position: Medical Director, Transplant Nephrology 
Keith R. Doram, MD 
Department of Medicine 
Division of General Internal Medicine/Geriatrics 
Position: Vice Chair for Clinical Affairs, Department of Medicine 
William F.lobst, MD 
Department of Medicine 
Division of Rheumatology 
Position: Vice Chair for Education, Department of Medicine 
Michael J. Pistoria, DO 
Department of Medicine 
Division of General Internal Medicine 
Position: Assistant Program Director, Internal Medicine Residency 
Program 
Status Changes 
Suzette V. Barreto, MD 
Department of Medicine 
Division of General Internal Medicine 
From: Provisional Active 
To: Associate 
Site of Privileges - LVH & L VH-M 
Theodore W. Eastland, MD 
Department of Family Practice 
From: Active 
To: Honorary 
Marla L. Jones, MD 
Department of Medicine 
Division of General Internal Medicine 
From: Provisional Active 
To: Associate 
Site of Privileges - LVH & L VH-M 
Charles F. Kelley, Jr., MD 
Department of Pediatrics 
Division of General Pediatrics 
From: Active 
To: Honorary 
Neal Kramer, DPM 
Department of Surgery 
Division of Orthopedic Surgery 
Section of Foot and Ankle Surgery 
From: Associate 
To: Provisional Active 
Site of Privileges - LVH-M 
Hugh J. O'Donnell, Jr., DDS 
Department of Dentistry 
Division of Pediatric Dentistry 
From: Active 
To: Associate 
Site of Privileges - LVH & L VH-M 
Geraldo A. Saavedra, MD 
Department of Medicine 
Division of Endocrinology-Metabolism 
From: Provisional Active 
To: Affiliate 
Site of Privileges - LVH & L VH-M 
Jeffrey W. Thompson, MD 
Department of Family Practice 
Division of Occupational Medicine 
From: Active 
To: Affiliate 
Site of Privileges - LVH & LVH-M 
John S. Wheeler, MD 
Department of Pediatrics 
Division of General Pediatrics 
From: Affiliate 
To: Honorary 
Douglas C. Wiseman, DO 
Department of Medicine 
Division of Allergy 
From: Associate 
To: Affiliate 
Site of Privileges - LVH & L VH-M 
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Two-Year Leave of Absence 
Stephen K. Klasko, MD 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Robert P. Oristagllo, DO 
Department of Medicine 
Division of General Internal Medicine 
Deborah L. Villeneuve, MD 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Additional One-Year Leave of Absence 
Karen M. Matz, MD 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Address Changes 
Wayne E. Dubov, MD 
Good Shepherd Physician Group 
Good Shepherd Outpatient-Cedar Crest 
1243 S. Cedar Crest Blvd. 
Allentown, PA 18103-7982 
(610) 776-3278 
Fax: (610) 402-5942 
Manny lyer, MD 
201 Drift Court 
Bethlehem, PA 18020 
(610) 865-5500 
Fax: (610) 861-3065 
Northampton Medical Associates 
•:• Michael S. Hortner, MD 
•:• Lisa H. Medina, MD 
•:• Daniel M. Spatz, Jr., MD 
6028 East 21st Street 
Suite 400 
Northampton, PA 18067-1247 
(610) 262-1519 
Fax: (610) 262-7125 
Address Correction 
Jonathan H. Munves, MD 
800 Ostrum Street 
Suite 102 
Bethlehem, PA 18015-1009 
Practice Changes 
Joseph J. Grassi, MD 
(No longer with Orthopaedic Associates of Bethlehem) 
Orthopedic Associates of the Greater Lehigh Valley 
3735 Easton Nazareth Highway 
Suite 101 
Easton, PA 18045-8338 
(610) 252-1600 
Fax: (610) 250-9257 
Gerald M. Zupruk, MD 
(No longer with Lehigh Valley Neurosurgery) 
Eastern Pennsylvania Neurosurgical Associates 
303 W. Broad Street 
Bethlehem, PA 18018-5526 
(61 0) 882-4460 
Fax: (610) 691-8384 
Resignations 
Joseph L. Antonowicz, MD 
Department of Psychiatry 
Section of Consultation-Liaison Psychiatry 
Darren G. Brenner, DMD 
Department of Dentistry 
Division of General Dentistry 
Thomas L. Carter, Jr., MD 
Department of Surgery 
Division of Cardio-Thoracic Surgery 
H. Thompson Dale, MD 
Department of Medicine 
Division of Cardiology 
Constance R. DIAngelo, MD 
Department of Pathology 
Division of Anatomic Pathology 
Section of Forensic Pathology 
Beth A. Folio, MD 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Samuel R. Giamber, MD 
Department of Medicine 
Division of Cardiology 
Donald P. Goldsmith, MD 
Department of Pediatrics 
Division of Pediatric Subspecialties 
Section of Rheumatology 
Charles Honeckman, DO 
Department of Pathology 
Division of Anatomic Pathology 
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Lila N. Inouye, MD 
Department of Pathology 
Division of Anatomic Pathology 
Anna Niewiarowska, MD 
Department of Medicine 
Division of Hematology-Medical Oncology 
Janet L. Osborne, MD 
Department of Obstetrics and Gynecology 
Division of Gynecology 
Section of Gynecologic Oncology 
Rajen P. Oza, MD 
Department of Medicine 
Division of Hematology-Medical Oncology 
Susan K. Pedott, DMD 
Department of Dentistry 
Division of Endodontics 
Peter R. Puleo, MD 
Department of Medicine 
Division of Cardiology 
Steven J. Svabek, DO 
Department of Surgery 
Division of Orthopedic Surgery 
Richard C. Wilson, MD 
Department of Medicine 
Division of Car~iology 
Yelena M. Yerrnak, MD 
Department of Psychiatry 
Section of Consultation-Liaison Psychiatry 
Allied Health Professionals 
Appointments 
Patti Sue Connolly, PA 
Physician Extender 
Physician Assistant- PA 
(Orthopaedic Associates of Allentown- Gregor M. Hawk, MD) 
Site of Privileges - L VH & L VH-M 
Ethyl C. Davis, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc - Alphonse A. Maffeo, MD) 
Site of Privileges - L VH & L VH-M 
Natalie L. Fahs, PA·C 
Physician Extender 
Physician Assistant- PA-C 
(Cedar Crest ENT Associates, PC- Theodore H. Gaylor, MD) 
Site of Privileges - LVH & LVH-M 
Number2 
Archie W. Hartzell, PA 
Physician Extender 
Physician Assistant- PA 
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(Orthopaedic Associates of Bethlehem, Inc- Thomas S. Sauer, MD) 
Site of Privileges - LVH-M 
David G. Kane, PA 
Physician Extender 
Physician Assistant- PA 
(Orthopaedic Associates of Bethlehem, Inc- Ranjan Sachdev, MD) 
Site of Privileges - LVH-M 
Erika L. Keller, CNM 
Physician Extender 
Professional - CNM 
(The Midwives & Associates Inc- Garry C. Karounos, MD) 
Site of Privileges - LVH 
Cynthia S. Kisner, PA·C 
Physician Extender 
Physician Assistant· PA-C 
(Peripheral Vascular Surgeons, PC -Victor J. Celani, MD) 
Site of Privileges - LVH & L VH-M 
Eileen M. Klang, LPN 
Physician Extender 
Professional - LPN 
(College Heights OBGYN Associates, PC - Thomas Hutchinson, MD) 
Site of Privileges - LVH & L VH-M 
Mary Ann T. Licwinko, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc- Alphonse A. Maffeo, MD) 
Site of Privileges - LVH & L VH-M 
Judith M. McDevitt, CRNP 
Physician Extender 
Professional - CRNP 
(The Heart Care Group, PC- Joseph L. Neri, DO) 
Site of Privileges - LVH & L VH-M 
Georgiann Morgan, RN 
Physician Extender 
Professional - RN 
(Opcor, PC- Fernando M. Garzia, MD) 
Site of Privileges - LVH & L VH-M 
Bradley A. Nace, PA-C 
Physician Extender 
Physician Assistant- PA-C 
(Lehigh Valley Orthopedic Group, PC - Randy Jaeger, MD) 
Site of Privileges - LVH & L VH-M 
Ann Jeanette Peiffer, PA·C 
Physician Extender 
Physician Assistant- PA-C 
(Opcor, PC- Fernando M. Garzia, MD) 
Site of Privileges - LVH & L VH-M 
Robert J. Peterson, PA-C 
Physician Extender 
Physician Assistant- PA-C 
(Orthopaedic Associates of Bethlehem, Inc - Peter W. Kozicky, MD) 
Site of Privileges • LVH-M 
Change of Supervising Physician 
Suzanne D. Amant, PA-C 
Physician Extender 
Physician Assistant- PA-C 
From: Gastroenterology Associates Ltd • Michael H. Ufberg, MD 
To: Gastroenterology Associates Ltd- J. Harry Pickle, MD 
Site of Privileges • LVH & L VH-M 
Dena L. Capobianco, PA-C 
Physician Extender 
Physician Assistant- PA-C 
From: Gastroenterology Associates Ltd • Michael H. Ufberg, MD 
To: Gastroenterology Associates Ltd- J. Harry Pickle, MD 
Site of Privileges - LVH & LVH-M 
Cynthia L. Dinsmore, CNM 
Physician Extender 
Professional - CNM 
From: M. Bruce Viechnicki, MD & Associates PC - M. Bruce 
Viechnicki, MD 
To: Lehigh Valley Women's Health Care Alliance- Carolyn Scott, MD 
Site of Privileges - LVH 
Wendy D. Grube, CRNP 
Physician Extender 
Professional- CRNP 
From: Stephen K. Klasko, MD 
To: OB-GYN at Trexlertown, PC- Larry R. Glazerman, MD 
Site of Privileges - LVH & L VH-M 
Cheryl L. Lichner, CRNP 
Physician Extender 
Professional - CRNP 
From: Stephen K. Klasko, MD 
To: 08-GYN at Trexlertown, PC- Larry R. Glazerman, MD 
Site of Privileges - LVH & LVH-M 
Janice A. Walck, CRNP 
Physician Extender 
Professional - CRNP 
From: Department of Medicine- John P. Fitzgibbons, MD 
To: Valley Gastroenterologists- Richard L. London, MD 
Site of Privileges - LVH & L VH-M 
Karen M. Williams, CRNP 
Physician Extender 
Professional - CRNP 
From: Department of Medicine- John P. Fitzgibbons, MD 
To: Good Shepherd Physician Group- Jane Dorval, MD 
Number2 
Additional Supervising Physician 
Constance A. Molchany, CRNP 
Physician Extender 
Professional - CRNP 
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Additional Supervising Physician: Robert X. Murphy, Jr., MD • Wound 
Healing Program at LVH-M 
Site of Privileges - LVH & L VH-M 
Resignations 








Jennifer M. Knights, PA-C 
Physician Extender 
Physician Assistant 
(Orthopaedic Associates of Allentown) 
Patricia A. Landis, CST 
Physician Extender 
Technical- Surgical Technician 
(Orthopaedic Associates of Bethlehem Inc) 
Chantal M. Lobo, CRNP 
Physician Extender 
Professional 
(ABC Family Pediatricians) 











Gregory R. Harper, M.D .. Ph.D. 
Physician in Chief, Cancer Services 
Suite 408 
1240 S. Cedar Crest Boulevard 
Allentown. PA 18103 
Phone: (610) 402-0512 Fax: (610) 402-0504 
E-mail: gregory.harper@lvh.com 
Lehigh Valley Hospital is committed to caring for all patients regardless of insurance coverage or 
ability to pay. For 25 years, this commitment to our community for patients with cancer and 
blood disorders has been through the oncology and hematology clinic, initially of the Lehigh 
Valley Hospital, and since 1993, at the John and Dorothy Morgan Cancer Center. 
The medical oncologists and hematologists at Lehigh Valley Hospital remain committed to 
caring for patients and their families regardless of financial circumstances. Starting in February 
2001, these patients will be seen in the private offices of our participating oncologists: Drs. Shah, 
Giangiulio, and Cormier, and Drs. Aviles, Barron, Harper, and Post. This change will enhance 
continuity of care, increase access to service, and facilitate flexibility in scheduling appointments 
at the convenience of the patient. 
All new patients requiring medical oncology/hematology consultation, whether inpatient or 
outpatient, and who are under insured will be referred to the John and Dorothy Morgan Cancer 
Center through 610-402-2273 (610-402-CARE). The request for referral will be communicated 
to the participating practice; the practice office will contact the referring physician (office) to 
obtain the appropriate information as they would for any referral, and the referring physician will 
be requested to talk to the consulting oncologist/hematologist before the appointment is 
confirmed. 
Consultation requests for radiation oncology will continue to be directed to 610-402-0700-this 
does not represent a change in current practice for referrals to radiation oncology. 
On behalf of the oncologists and hematologists at the John and Dorothy Morgan Cancer Center, 
I am pleased to announce this change, which we believe will lead to improved physician and 
patient satisfaction with our cancer services. 
Wishing you all the very best in the New Year. 
Sincerely yours, 
Gregory R. Harper, MD, Ph.D. 
Physician in Chief 
Publications 
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Press Release 
ALERT - PHYSICIAN SCAM - ALERT 
The following has recently come to the attention of the Drug Enforcement 
Administration, Office of Diversion Control: 
The Medical Society of New Jersey has recently learned that con artists have targeted 
physicians with a phony questionnaire asking for vital, confidential information, 
including the physician's DEA numbers, social security number and credit card data. 
The New Jersey State Attorney General is investigating this mailing sent to physicians 
on what appears to be New Jersey Division of Consumer Affairs letterhead, which 
seeks to "update" physician "profiles in our system." The letter claims that by 
responding, a physician could order controlled dangerous substances over the phone 
or via the internet. 
Not only could the solicited personal information make the physician a victim of 
financial fraud, but the confidential professional information - such as DEA number-
could facilitate illegal drug trafficking. In fact, the fraudulent questionnaire asks the 
physician to provide two signature samples ... "as you sign on your prescription pad." 
Do not respond if you have received such a questionnaire. The Division of Consumer 
Affairs verifies that this is not their mailing, and that the return address with a Newark 
post office box is for a non-government entity. Contact the Division of Consumer Affairs 
at 1-800-242-5846 or the New Jersey State Board of Medical Examiners at 
609-826-7100 if you have any doubts regarding the authenticity of any document 
received from a state agency. 
If you believe that you may have recently filled out and sent in such a questionnaire, 
immediately contact the Consumer Affairs Enforcement Bureau during regular business 
hours at 973-504-6300. 
The Medical Society of New Jersey is assisting the Division of Consumer Affairs in 
alerting physicians about this scam and will continue to update you as necessary. 
Continue to check www.msnj.org for additional postings. 
If you reside outside of New Jersey and have experienced a similar inquiry, please 
contact your state professional board and/or consumer affairs division. Always 
safeguard your personal and professional data. Always verify the need and authority of 





News from the Library 
OVID Training. 
The Library has completely converted to OVID's on-
line MEDLINE system. This Web-based system is 
updated daily by Ovid. Call Barbara Iobst in the 
Health Sciences Library at 610-402-8408 to schedule 
a one-on-one training session. 
New Publications in the CC Campus Library. 
"Cultural Competence Compendium" 
Author: American Medical Association 
Description: This publication "includes resources for health 
care and communication issues confronting people from 
underrepresented and underserved racial, ethnic, and 
socioeconomic groups and those with physical and mental 
illnesses or disabilities." 
New Publications in the 17 Street Library. 
"Mayo Clinic's Complete Guide for Family Physicians and 
Residents in Training" 
Author: R. Bratton 
Description: "This guide takes a different approach aimed at 
-the individual physician or resident physician and focuses on 
what this person can expect and how to survive the labors of 
residency training and being in family practice." It includes 
information on consultation/ 
referrals, teaching, time management, computers, osteopathic 
medicine in family practice, board certification/recertification 
etc. ' 
New Publications in the LVH-Muhlenberg Library. 
"Pocket Atlas of Emergency Medicine" 
Author: K. Knoop, et al. 
1 
Computer-Based Training (CBT): 
Computer Based Training (CBT) programs are available for 
L VHHN staff. Topics covered by the CBT programs include: 
Access 2.0 Power-Point 4.0 
Windows NT 4 Word 97 
Excel 97 Access 97 
PowerPoint 97 Lotus 1-2-3 Millennium 
WordPerfect 8 E-mail GUI 
PHAMIS LastWord Inquiry Only commands 
CBT programs replace the instructor-led classes previously 
held at Lehigh Valley Hospital. A proctor will be in the room 
with the learner while he/she takes the CBT, but the learner 
will control the pace and objectives of the learning. 
Computer Based Training takes place in Suite 401 of the John 
& Dorothy Morgan Cancer Center (the computer training 
room) and in the Muhlenberg Hospital Center computer 
training room (offthe front lobby). The schedule of 
upcoming dates is as follows: 
CBT sessions for JDMCC, suite 401 are as follows: 
March 13, 8 am- Noon 
Sessions at MHC, I.S. Training room are as follows: 
March 20, Noon- 4pm 
Twelve slots are available for each session. 
To register, please contact Suzanne Rice via e-mail or at 484-
884-2560 with the following: 
date of session 
second date choice 
department 
phone number 
You will receive an e-mail confirming your choice within two 
business days. If you have any questions, please contact Craig 
Koller at 610-402-1427 or through e-mail. 
Any questions, concerns or comments on articles from CEDS, please 
contact Bonnie Schoeneberger 610-402-1210 
---
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Center for Educational Development and Support (CEDS) 
moving 
February 9, 2001 
to 
17th & Chew Street 
Director CEDS 
Martyn 0. Hotvedt, Ph.D. 610-402-2561 
Nursing Education 
Susan Steward (Director) 610-402-2481 
Kelly Beauchamps 610-402-2482 Kathy Hsu 610-402-2483 
Sandy Blackledge 610-402-2342 Diane Kocsis 610-402-2343 
Lyn Case 610-402-2313 Barry Mitchneck 610-402-2338 
Jeanine DeLucca 610-402-2345 Donna Stout 610-402-2277 
Edie Gray 610-402-2348 Ann Zeravsky 610-402-2814 
Ladene Gross 610-402-2347 
Patient Education 
Rita Bendekovits (Manager) 610-402-2379 
Arlene Adamczak & Barbara Caserta 610-402-2484 
Medical Education 
Rosanne Rishko (Manager) 610-402-2591 
Any Snyder 610-402-2554 
Continuing Education 
Bonnie Schoeneberger 610-402-2584 
Grants & Community Outreach 
Sallie Urffer (Manager) 610-402-2556 
Secretary 610-402-2501 
Office of Educational Technology 
John Frankenfield (Director) 610-402-2408 
Ina Ashford 610-402-2410 
Craig Koller 610-402-2413 
Suzanne Rice 610-402-2475 
Christopher Sarley 610-402-2427 
Gary Weisel 610-402-2505 
Palliative Care 







Center for Educational Development and Support 
1"th & Chew Street 
PO Box 7017 
Allentown, PA 18015-7017 
Inner office mo1'ling address: 
Center for Educational Development and Support 
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THERAPEUTICS AT A GLANCE 
The following actions were taken at the November· December 2000 Therapeutics Committee Meeting- Clinical Pharmacy Services 
Joseph Ottinger, R.Ph., MS, MBA, Christopher Moore, Pharm.D., Janine Barnaby, R.Ph. ' 
Herbal Anticoagulants 
I have been asked to provide a list of herbal 
remedies that have demonstrated antiplatelet 
activity or those that can affect bleeding times. 
It is important to remember that the discovery 
of warfarin was related to the observation that 
a group of bovines who ingested spoiled clover 
silage died from internal hemorrhage. 
Therefore it is not unrealistic that other plant-
derived medicinals could have similar effects. 
Please remember that some of the data comes 
from in vitro studies and case reports. 
However it is important to take these factors 
into consideration when treating patients who 
take herbal remedies. Please consider the 
acknowledgment of herbal remedies when 
taking patient histories. At LVH, we treat 
herbal remedies as medications. 





































This list was modified from The Coumadin 
Drug and Herbal Product Guide, Dupont 
Pharma Inc. The authors of this reference 
cited numerous references from peer reviewed 
medical literature. 
Budesonide For Pediatrics 
Therapeutics Committee has approved the 
addition of budesonide suspension for 
inhalation to L VH formulary. This agent is a 
significant addition because it represents the 
only commercially available form of nebulized 
corticosteroid. It is currently only indicated 
for children. (12 months to 8 years of age) 
Please be aware that the drug requires the use 
of a jet-nublizer NOT an ultrasonic nebulizer. 
Alendronate Weekly 
Alendronate 70 mg tablets were added to L VH 
formulary. In clinical trials, it was 
demonstrated that the drug has the same 
efficacy and same incidence of side effects 
when administered by this method. This 
addition will hopefully promote patient 
compliance and decrease the risk of an adverse 
drug reaction as opposed to administering 
seven - 10 mg tablets once per week. 
ADR Reporting 
The quantity of Suspected ADR reports for the 
third quarter of 2000 were significantly 
reduced. The incidence ratios were the lowest 
on record. Unfortunately, this was felt to be 
due primarily to a decline in reports from 
pharmacist -based observers. Staff pharmacists 
were alerted to this trend and have responded 
appropriately. Suspected incidents continue to 
represent a 'normal' pattern of manifestations 
consistent with the level of usage of specific 
groups of agents and the volume of activity in 
certain clinical areas. Only three 11 Severe 11 
case reports were identified. With two of these 
episodes being the primary reason for the 
patient's admission to the hospital. An 
increase in reporting reactions from oncology 
areas continued; marking the second straight 
quarter where improved reporting was noted. 
This was principally perceived to be the direct 
result of additional clinical pharmacist 
interventions. One of the outcomes of this 
reporting was the development of a 
Hypersensitivity treatment Protocol to be 
published in this newsletter under a separate 
heading. 
All health-care personnel are encouraged to 
report suspected adverse drug reactions. 
Copies of the Suspected Adverse Drug 
Reaction Documentation Form are available in 
all patient care areas. Complete as many 
portions of the form as you can or at least 
notify the Pharmacy staff of your observations. 
A pharmacist will review the case and 
complete/initiate the form as necessary. ALL 
REPORTS are confidential and they are 
summarized and presented to the Therapeutics 
committee. Cause-effect analysis and trending 
considerations are reviewed in this process. 
Patient allergy data are updated in accordance 
with the level of suspicion based on the 
Naranjo scale and patient's may receive 11 ID 11 
cards describing the nature of the reactions and 
the presumed associated cause. This 
information card can be carried by the patient 
and presented in future health-care 
interventions requiring drug treatments. 
Following are the particulars for this quarter 
~ 2nd0tr 
Reports per 10,000 doses 0.52 0. 63 
Reports per 1,000 admissions 4.09 5.53 
Third Quarter Data 
Table 1: Adverse Reactions By Reporter 
Reoorter tf.. Re!lOrts % ReilQrts 
Pharmacist 24 52.1 
Nurse 17 37.0 
X-Ray Technician 4 8.7 
Physician __ 1 2.2 
TOTAL 46 100 























































Table 4: Adverse Reaction Severity 
Classification !!.. Re!lorts ~ Re!lorts Most Common 
Mild 17 37.0 Contrast dye- 6 
Moderate 26 56.5 abcix w/hep;inflix-3 
Severe _3 6.5 see case 




Argatroban is indicated for use as an 
anticoagulant for prophylaxis or treatment of 
thrombosis in patients with heparin-induced 
thrombocytopenia (HIT). Argatroban may also 
have potential utility in disseminated 
intravascular coagulation (DIC), as an adjunct to 
thrombolytic agents in the treatment of acute 
myocardial infarction, heparin-induced 
thrombosis syndrome, and stroke. Other agents 
used in patients with heparin-induced 
thrombocytopenia are danaparoid and lepirudin. 
The FDA-approved indications for argatroban and 
lepirudin are summarized in Table 1. 
Table 1: FDA-Approved Indications for 
Argatroban and Lepirudin: 
Indication Argatroban Lepirudin 
Anticoagulation for X 
prophylaxis of 
thrombosis in 
patients with HIT 
Anticoagulation for X X 
treatment of 
thromboembolic 
disease (to prevent 
further 
complications) in 
patients with HIT 
HIT occurs in 1% to 5% of the patients treated 
with unfractionated heparin. Generally, HIT 
develops after 5 to 8 days of heparin therapy, but 
it may occur earlier in patients who have received 
heparin therapy during the previous 3 months. It 
can result in numerous thrombotic complications, 
such as stroke, myocardial infarction, deep venous 
thrombosis, pulmonary embolism, and ischemic 
damage of a limb. The risk of developing HIT is 
higher with porcine heparin than beef heparin, 
unfractionated heparin than low-molecular-weight 
heparin, and patients treated with high-dose 
heparin versus low-dose heparin. 
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Acute HIT is managed by the discontinuation of 
the heparin therapy. Warfarin is not used as a 
substitute for the heparin during acute HIT 
because it can deplete protein C and cause 
microvascular thrombosis. Warfarin therapy 
should be delayed until the platelet count has 
returned to normal levels. Low molecular weight 
heparins are also not universal substitutes for 
heparin in a patient with acute HIT because 
platelet aggregation cross-reactivity in vitro has 
been demonstrated with some of these products. 
Danaparoid, a heparinoid, may be useful in some 
patients. Danaparoid has a lower risk of 
nonidiosyncratic platelet activation and less cross-
reactivity for HIT -IgG than unfractionated heparin 
and the other low molecular weight heparins. 
Hirudin, a recombinant antithrombin similar to 
that found in the salivary gland of a medicinal 
leech, is another potential alternative agent. 
Argatroban and lepirudin are approved for use as 
an anticoagulant for the treatment of 
thromboembolic disease in patients with HIT and 
argatroban is approved for the prophylaxis of 
thrombosis in patients with HIT. 
CLINICAL PHARMACOLOGY: Argatroban 
is a synthetic, reversible direct thrombin inhibitor. 
Argatroban is highly selective for thrombin. At 
therapeutic concentrations, it has little or no effect 
on related serine proteases (trypsin, factor Xa, 
plasmin, and kallikrein). It can inhibit the action 
of both free and clot-associated thrombin. 
Argatroban also inhibits the form~tion of 
thrombin-antithrombin III (A Till) complexes by 
competing with A Till for thrombin. By inhibiting 
the catalytic site of thrombin, argatroban 
subsequently affects the conversion of fibrinogen 
to fibrin, the formation of the thrombin-
antithrombin III complex, platelet aggregation, the 
release of plasminogen activator from vessel walls 
and activation of factors V, VIII, and XIII. 
Argatroban does not accelerate the consumption 
of A Till, in contrast to heparin, but rather is 
consumed in lieu of A Till and is thus potentially 
useful in A Till -deficient situations. In addition, 
it appears to reduce the vasomotor effects of 
thrombin. 
This is significant in the treatment of certain 
pathologies. For example, A Till -deficient 
patients see a greater occurrence of thrombosis 
and A Till is decreased in disseminated 
intravascular coagulation (DIC). Heparin is 
dependent on ATIII for its activity while 
argatroban works independently of the blood 
component. Argatroban is not neutralized like 
heparin by platelet products (factor IV) and is 
more effective against clot-bound thrombin than 
hirudin. Clot-bound thrombin is resistant to the 
inhibitory effects of the heparin-ATIII complex. 
In contrast, argatroban inhibits clot-bound as well 
as free thrombin. 
When administered by continuous infusion, 
anticoagulant effects and plasma concentrations 
follow similar, predictable temporal response 
profiles, with low intersubject variability. 
Immediately upon initiation of infusion, 
anticoagulant effects are produced as plasma 
argatroban levels begin to rise. Steady-state levels 
ofboth drug and anticoagulant effect are typically 
attained within 1 to 3 hours and are maintained 
until the infusion is discontinued or the dosage 
adjusted. Dissipation of the anticoagulant effects 
was about 4-fold faster for argatroban than 
heparin. Argatroban' s reversible inhibition, in 
comparison to hirudin's essentially irreversible 
inhibition, may represent a distinct advantage. 
Rapid dissociation of argatroban from thrombin 
would be expected to lead to a more rapid return 
of aPTT and ACT to normal values (see Table 2). 
However, this reversibility may also be associated 
with a greater propensity for induction of a 
hypercoagulable state after administration is 
terminated. 
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Table 2: Comparison of Selected 
Anticoagulants: 
Argatroban Heparin Hirudin Lepirudln 
Molecular Weight (D) 526.66 12,000 7,000 6979.5 
Direct Thrombin Inhibition Yes No Yes Yes 
Inhibition Speed Fast Fast Slow Slow 
Thrombin Binding Affinity + I ++ +++ +++ 
Reversibility Reversible Reversible Irreversible Irreversible 
Effect on a.P1T ++ +++ +++ 
Effect on PT ++ + +++ 
Effect on TI ++ +++ +++ 
Inhibition of Clot-Bound +++ 0 + 
Thrombin 
Antithrombotic Efficacy +++ ++ +++ 
Hemorrhagic Potential ++ +++ +++ 
Inhibition ofThrombolysis 0 0 0 
Argatroban does not interact with heparin-
induced antibodies. Antibody formation to 
argatroban has not been observed. 
PHARMACOKINETICS: Argatroban binds 
rapidly to thrombin at the catalytic site and 
apolar region at a diffusion controlled rate. 
Since anti thrombotic efficacy of thrombin 
inhibitors requires rapid complete inhibition of 
local thrombin concentrations, a more rapid 
association rate (as argatroban possesses versus 
hirudin) may translate into a clinical advantage. 
The mean half-life of argatroban is about 40 
minutes. Argatroban is primarily metabolized 
by hydroxylation and aromatization in the liver 
to four known metabolites. Cytochrome P450 
3A4/5 enzyme has been identified to catalyze 








does not appear to play a significant role in the 
in vivo metabolism of argatroban. 
The pharmacokinetics of argatroban were not 
altered in subjects with mild, moderate, or 
severe renal impairment. Renal impairment 
appears to only mildly influence aPTT and ACT 
values achieved while receiving argatroban. 
Dosage adjustments are recommended in 
patients with hepatic impairment. 
COMPARATIVEEFFICACY: FDA 
approval was granted on the bases of a 
historically controlled efficacy and safety study 
and a follow-on efficacy and safety study. 
CONTRAINDICATIONS, WARNINGS, AND 
PRECAUTIONS: Argatroban is contraindicated 
in patients with overt major bleeding, and in 
patients hypersensitive to argatroban or an of the 
product ingredients (D-sorbitol, dehydrated 
alcohol)' Individuals with a condition 
predisposing them to a bleed should also be 
assessed for the benefit of therapy with argatroban 
and be closely monitored. Examples of conditions 
that might put a person at risk ofbleeding include 
duodenal and gastric ulcers, history of a recent 
operative or invasive procedure, renal 
insufficiency, sub-acute bacterial endocarditis, or 
thrombocytopenia. 
Argatroban should be used with extreme caution 
in disease states and other circumstances in which 
there is an increased risk of hemorrhage, 
When argatro ban therapy needs to be 
discontinued, some sources have recommended 
tapering the dose instead of abruptly discontinuing 
the drug. Abrupt discontinuation may lead to a 
hypercoagulable state since some patients have 
shown an increase in concentration of thrombin-
antithrombin III complex within 2 hours of 
discontinuation of the argatroban infusion. 
Page25 
In patients with hepatic impairment, therapy 
should be initiated at a lower dose and carefully 
titrated. Upon discontinuation of therapy, full 
reversal of anticoagulant effects may require 
longer than 4 hours due to decreased clearance. 
The safety and effectiveness of argatroban have 
not been established in patients under 18 years of 
age. 
Argatroban is in Pregt?.ancy Category B. 
ADVERSE EFFECTS: The side effects reported 
with argatroban include hypotension, fever, 
diarrhea, ventricular tachycardia, vomiting, 
bleeding, hemorrhage, dizziness, headache, 
injection site reactions, nausea, pain, rash, and 
rebound anginal symptoms. In addition, increases 
in serum transaminases have been reported. 
Table 3: Adverse Events in the Historically 
Controlled Trials of Argatroban: 
Events Argatroban Controlll 
(n-568) (n•193) 
Major H~morrhaglc EwntJ 
Gastrointestinal 2.3% 1.6% 
Genitourinary and hematuria 0.9% 0.5% 
Decrease hemoglobin/hematocrit 0.7% 0% 
Multisystem hemoiThage and DIC 0.5% I% 
Limb and BKA stump 0.5% 0% 
Intracranial hemoiThage O"AI O.S% 
Minor H-rrhaglc EventJ 
Gastrointestinal 14.4% 18.1% 
Genitourinary and hematuria 11.6% 0.8% 
Decrease hemoglobin/hematocrit 10.4% 0% 
Groin 5.4% 3.1% 
HemoptySis 2.9% 0.8% 
Brachial 2.4% 0.8% 
Non-h-rrhaglc Events 
Dyspnea 8.1% 8.8% 
Hypotension 7.2% 2.6% 
Fevet 6.9% 2.1% 
DiiiiThea 6.2% 1.6% 
Sepsis 6% 12.4% 
Cardiac mest 5.8% 3.1% 
Nausea 4.8% 0.5% 
Ventricular tachycardia 4.8% 3.1% 
Pain 4.6% 3.1% 
Urinary tract infection 4.6% 5.2% 
Vomiting 4.2% 0% 
Infection 3.7% 3.6% 
Pneumonia 3.3% 9.3% 
Atrial fibrillation 3% 11.4% 
Coughing 2.8% 1.6% 
Abnormal renal function 2.8% 4.7% 
Abdominal pain 2.6% 1.6% 
Cetebrovascuiat disorder 2.3% 4.1% 
Allergic reactions were reported in 156 patients 
receiving argatrob~n in other studies. 
Approximately 95% of these reactions occurred in 
patients receiving concomitant streptokinase 
and/or contrast media. 
DRUG INTERACTIONS: Concomitant use of 
argatroban with anti platelet agents, thrombolytics, 
and other anticoagulants may increase the risk of 
bleeding. 
Pharmacokinetic interactions between argatroban 
and warfarin have not been observed; however, 
concomitant administration does result in 
prolongation of the PT and INR (see Monitoring). 
The combination of argatroban and warfarin does 
not result in further reduction in vitamin K 
dependent factor Xa activity than that which is 
seen with warfarin alone. 
MONITORING: The aPTT values must be 
monitored in all patients. Anticoagulation effects 
associated with argatroban at doses up to 40 
meg/kg/min are well correlated with the aPTT. 
The aPTT and ACT are both effective for 
monitoring argatroban therapy. The aPTT can be 
used monitor argatroban at levels of 0.04 to 2.5 
mcg/mL. The ACT can be used to monitor higher 
levels of argatroban (1 to 15 mcg/mL) achieved 
during revascularization procedures. 
The aPTT should be monitored daily as well as 2 
hours after the start of infusion and 2 hours after 
each dosage adjustment. The aPTT should be 
kept within 1.5 to 3 times control. Current 
laboratory 'normal' aPTT is 20.6-37.7 seconds. 
Prothrombin time or INR cannot always be 
reliably used to monitor warfarin while patients 
on argatroban are being converted to oral 
anticoagulant therapy, as argatroban 
synergistically interferes with the INR. The 
relationship between INR on co-therapy and 
warfarin alone is dependent on the dose of 
argatroban and the thromboplastin reagent used. 
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INR should be measured daily while argatroban 
and warfarin are coadministered. In general, with 
argatroban doses up to 2 meg/kg/min, argatroban 
can be discontinued when the INR is greater than 
4 on combined therapy. After argatroban is 
discontinued, the INR should be measured in 4 to 
6 hours. If the repeat INR is below the desired 
range, argatroban therapy should be resumed and 
the procedure repeated daily until the desired 
therapeutic range with warfarin is achieved. For 
argatroban doses greater than 2 meg/kg/min, the 
dose should be temporarily reduced to a dose of2 
meg/kg/min and the INR measured 4 to 6 hours 
later. 
No antidote/antagonist presently exists for 
argatroban; however, its relatively rapid clearance 
from the plasma nearly eliminates a need for such 
an agent. At therapeutic levels, anticoagulation 
parameters usually return to normal within 2 to 4 
hours after discontinuation of argatroban, 
although reversal may take longer in patients with 
hepatic impairment. 
DOSING: Prior to initiating therapy, heparin 
therapy should be discontinued and a baseline 
aPTT obtained. The recommended initial dose for 
adult patients with IDT, and without hepatic 
impairment, is 2 meg/kg/min, administered as a 
continuous infusion. The aPTT should be 
checked 2 hours after initiation of therapy to 
confirm the aPTT is within the desired range, and 
dosage adjustments made as necessary. The dose 
can be adjusted as clinically indicated, but not to 
exceed 10 meg/kg/min, until the steady-state 
aPTT is 1.5 to 3 times the initial baseline (not to 
exceed 100 seconds). 
For patients with moderate hepatic impairment, an 
initial dose of 0.5 meg/kg/min is recommended, 
based on the approximately 4-fold decrease in 
argatroban clearance compared to patients with 
normal hepatic function. The aPTT should be 
monitored closely and the dosage adjusted as 
needed. 
Some sources have recommended argatroban 
therapy be tapered rather than abruptly halted 
when it needs to be discontinued. 
CONCLUSION: Argatroban appears to be a 
useful agent in the treatment of patients with 
heparin-induced thrombocytopenia, although 
comparative data with lepirudin and danaparoid 
are lacking. Its usefulness in the treatment of 
other conditions will require documentation from 
controlled clinical trials and will be dependent on 
the drug's cost and safety. Argatroban may offer 
a safety advantage over lepirudin, in that it is 
shorter acting and rapidly eliminated even in 
patients with renal impairment. In addition, it 
appears to inhibit thrombin faster; inhibits clot-
bound thrombin to a more significant degree than 
lepirudin. The cost of a single therapy day for an 
80 kg patient with normal renal/hepatic function 
is estimated to be $875 per day (lepirudin) vs 
$600 per day (argatroban). Argatroban would 
appear to be an agent that should be added to the 
L VH Drug formulary for selected use in those 
patients needing parenteral anticoagulation where 
heparin products may be deleterious. The 
Therapeutics Committee recommended that it 
replace lepirudan given the current information. 
Lamisil Rejected 
Terbinafine (Lamisil®) cream was not approved 
to be added to L VH formulary. Instead, an 
autosub with clotrimazole (Lotrimin®) will be 
instituted. In studies comparing the two agents, 
both were equally efficacious against tinea pedis, 
cruris and corporis due to E.floccosum, T. 
mentagrophytes or T .rubum, Clotrimazole also 
showed greater activity against Candida. The dose 
of clotrimazole will be 1 application twice daily. 
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Hypersensitivity Protocol 
Therapeutics committee approved a 
hypersensitivity protocol for use throughout the 
hospital. The protocol originated in the 
hematology/oncology division for use in these 
patients and a checkbox was added to the 
antineoplastic order sheet. The rationale is that the 
nurses can start to administer medication 
(specifically diphenhydramine) to the patient 
while waiting for the physician to call back with 
further orders. 
The protocol is as follows: 
1. Stop infusion page physician 
immediately 
2. NSS IOOmllhr 
3. Monitor BP, pulse, Sa02 
4. Give diphenhydramine 50mg IV and have 
epinephrine 1 : 1 000 available 
5. 2Limin 0 2 as needed 
A check box is being added to all physician order 
sheets which will be located aside of the check off 
box stating no allergies. By checking the box, the 
hypersensitivity protocol will be enacted in case 
of a hypersensitivity reaction. 
Heparin Order sheet 
A revised intravenous heparin order sheet has 
been developed to facilitate use of this important 
agent. The order sheet will contain the more 
widely used dosing schemes, but physicians will 
be able to describe individually tailored regimens 
for those patients that would benefit from such 
alterations. The order format incorporates the 
new therapeutic ranges identified in the LAB 
LINK. A copy of the two sided form is attached 
to this newsletter. 
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HEPARIN ORDER SHEET 
DRUG INTOLERANCES: REACTIONS: 
DRUG ALLERGIES: REACTIONS: 
NONE KNOWN 
telected Protocols for Treatment and heparin dose 
djustments are listed on the reverse side of this 
form 
If the patient _lli ~candidate for Low Molecular Weight heparin for the treatment of uncomplicated DVT with Q! without!%. 
enoxaparin lmglkg g 12h ~ or u mm g24h ~ has been shown to be as equally efficacious and safe as unfractionated heparin. 
Please initiate the "Ou:toatient" DVT treatment protocol and use that order set. 
Height= Current laboratory standards for aPTT are listed below: 
Normal= 21-38 seconds 
Equivalent therapeutic aPTT range for 0.3- 0.7 units/ml heparin level (based on anti-factor Xa 
activity)= 68-113 seconds 
Weight (kg)= 
1.:. Identify reason for use (CHECK ONE): Unstable angina/MI Treatment of DVT/PE 
Stroke Other 
SELECT TREATMENT REGIMEN (CHECK ONE) 
£: Use "Cardiac" dosing protocol (ACC/AHA Modei)-See reverse side gforder. 
Use Modified Raschke dosing protocol <PEIDVD-See reverse side gf order. 
Use StrokeffiA dosing protocol. See reverse side gf order. 
Use specific dosing regimen identified below (Must describe heparin dose modifications and PTT targets 
on this order sheet below) 
.1. Obtain baseline • aPTT, CBC prior to initiating therapy. if not already done in previous 24 hr 
period. If baseline aPTT elevated, call physician to notifv. 
4. Obtain patient weight in kg, prior to initiating theraov. Complete weight field 
~ Obtain aPTT ~ hours after each dosing adJustment until targeted aPTT range is achieved. Modify dose as 
directed ~ preselected protocol or as directed below. Once targeted aPTT range is achieved. obtain aPTT 
dai~ to monitor. 
6. Obtain platelet count every ~ Call if platelet count <100,000/mm3 
1. 1f heparin dose i.§. greater than 20 units/kg hr without attaining 9. targeted aPTT. obtain HEPARIN LEVEL 
Yes No 
8. Test all stools for occult blood 
9 Make all dosing adjustments as prompt!~ as possible as directed. Round all doses to the nearest 100 units. 
Dosing scale must be completed below, if none ofthe formatted protocols is selected above 
Initial heparin bolus: units now. 
Immediately follow with infusion ofheparin 25,000 units/ 250 mls (100 units/ml) and adjust the infusion rate as 
follows: (Only Complete if you checked off 'specific dosing protocol 








ACC/AHA <Cardiac Protocol) Loading dose of 60 units/kg (maximum bolus 4.000 units). followed J2y an initial infusion rate of 12 
unitslkglhr (maximum 1.000 units/hr. Adjust as indicated below. 
Cardiac heparin protocol adjustments 
PTI <38 Give 40 unit/kg bolus (maximum 4,000 units):increase heparin infusion rate by 
I 00 unitslhr ( <80kg) OR 
200 unitslhr (~80kg) 
PTI 38-55 Give 20 unit/kg bolus; increase heparin infusion rate by 
100 unitslhr (all weights) 
PTI 56-67 Increase heparin infusion by 
100 unitslhr (all weights) 
PTI 68-95 NO CHANGE 
PTI 96-125 Decrease heparin infusion rate by 
I 00 units/hr (all weights) 
PTI 126-160 Decrease heparin infusion rate by 
I 00 unitslhr ( <80kg) OR 
200 units/hr (~80kg) 
PTI 161-200 Stop heparin for I hour. Decrease heparin infusion rate by 
200 units/hr ( <80kg) 
300 unitslhr (~80kg) 
PTI> 200 CALL PHYSICIAN FOR FUR TilER ORDERS 
Page29 
Raschke (DVT/PE protocol) Loading dose of 80 units/kg, followed by m initial infusion rate of 18 units/kg/hr. Target PTT 1.5-2.5 
times PTT control. Adjust M indicated below. 
Modified Raschke heparin protocol adjustments <PEIDVT) 
PTI < 38 80 unit/kg bolus. Increase infusion rate by 
4 units/kglhr 
PTI 38-67 40 units/kg bolus. Increase infusion rate by 
2 units/kglhr 
PTI 68-ll3 NO CHANGE 
PTT 114-140 Reduce infusion rate by I unitslkglhr 
PTT 141-170 Reduce infusion rate by 2 units/kglhr 
PTT 171-210 Hold heparin for one hour. Reduce infusion rate by 3 units/kg/hr. 
P~21 0 CALL PHYSICIAN FOR FUR1HER ORDERS. 
Stroke/TIA protocol Loading dose not recommended. Initiate infusion rate at 15 units/kg/hr. Adjust as Indicated 
below 
Strokefl'IA heparin protocol adjustments 
PTI <55 Increase infusion rate by 100 units/hr 
PTT 55-ll3 NO CHANGE 
PIT 114-150 Decrease infusion rate by 100 unitslhr 
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